ClinicalTrials.gg
CompletedNCT03403439Updated Nov 28, 2025Results posted

This Study in Healthy Men Tests How Itraconazole Influences the Amount of BI 1015550 in the Blood

A Phase 1 interventional study of BI 1015550 and itraconazole in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The primary objective of this trial is to investigate whether and to what extent co-administration of multiple doses of itraconazole affect single dose pharmacokinetics of BI1015550, i.e. to compare the relative bioavailability of 6 mg BI 1015550 when given alone (reference, treatment R) to the relative bioavailability of 6 mg of BI 1015550 given on the 4th day of a 12-day-treatment with itraconazole (test, treatment T) following oral administration in healthy male subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects according to the assessment of the investigator, based on a complete medical history including a physical examination, vital signs (BP (Blood Pressure), PR (Pulse Rate)), 12-lead (Electrocardiogram), and clinical laboratory tests
  • Age of 18 to 55 years (incl.)
  • of 18.5 to 29.9 kg/m2 (incl.)
  • Signed and dated written prior to admission to the study in accordance with GCP and local legislation

Exclusion criteria

Exclusion Criteria:

  • Any finding in the medical examination (including BP (Blood Pressure), PR (Pulse Rate) or (Electrocardiogram)) is deviating from normal and judged as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 bpm (beats per minute)
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease judged as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy and simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders, including but not limited to mood disorders and any history of suicidality.
  • History of relevant orthostatic hypotension, fainting spells, or blackouts
  • Chronic or relevant acute infections
  • History of relevant allergy or (including allergy to the trial medication or its or other Azoles )
  • Use of drugs within 30 days prior to administration of trial medication if that might reasonably influence the results of the trial (incl. /QTc interval prolongation)
  • Participation in another trial where an drug has been administered within 60 days prior to planned administration of trial medication, or current participation in another trial involving administration of investigational drug
  • Further exclusion criteria apply
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    BI 1015550 alone (R) / itraconazole + BI 1015550 (T)

    Participants were administered single dose of BI 1015550 6 milligram (mg) tablet orally with 240 milliLitre (mL) of water after an overnight fast of at least 10 hours on Day 1 of Visit 2. Again participants were administered itraconazole plus BI 1015550; participants received 12 days of itraconazole treatment (200 mg itraconazole solution given orally once daily with 240 mL of water after an overnight fast of at least 9 h) from Day -3 to Day 9 of Visit 3 combined with a single dose of 6 mg BI 1015550 on the fourth day (Day 1) of the itraconazole treatment (1 hour after the itraconazole administration). The BI 1015550 single doses of treatments R and T were separated by a wash-out period of at least 10 days.

    Drug: BI 1015550 · Drug: itraconazole

Interventions

  • single dose of BI 1015550 6 milligram (mg) tablet orally with 240 milliLitre (mL) of water after an overnight fast of at least 10 hours

    Also known as: Nerandomilast, JASCAYD®

  • 200 mg itraconazole solution given orally once daily with 240 mL of water after an overnight fast of at least 9 h

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 to 119 Hours

    Area under the concentration-time curve of BI 1015550 in plasma over the time interval from 0 to 119 hours (h) (AUC0-119). Standard error is actually geometric standard error. Geometric mean (gMean) is actually adjusted geometric mean. Pharmacokinetic samples were collected at 3:00 hours:minutes (h:m) prior to drug administration and at 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00, 34:00, 47:00, 71:00, 95:00 and 119:00 h:m after drug administration during Visit 2 and Visit 3. Additionally at 143:00, 167:00, 191:00 and 215:00 h:m after drug administration during Visit 3.

    Time frame: Up to 215 hours (Please check measure description for detailed timeframe)

  2. Maximum Measured Concentration of the BI 1015550 in Plasma

    Maximum measured concentration of the BI 1015550 in plasma (Cmax). Standard error is actually geometric standard error. Geometric mean is actually adjusted geometric mean. Pharmacokinetic samples were collected at 3:00 h:m prior to drug administration and at 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00, 34:00, 47:00, 71:00, 95:00 and 119:00 h:m after drug administration during Visit 2 and Visit 3. Additionally at 143:00, 167:00, 191:00 and 215:00 h:m after drug administration during Visit 3.

    Time frame: Up to 215 hours (Please check measure description for detailed timeframe)

Secondary outcomes

  1. Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)

    Area under the concentration-time curve of BI 1015550 in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf). Standard error is actually geometric standard error. Geometric mean is actually adjusted geometric mean. Pharmacokinetic samples were collected at 3:00 h:m prior to drug administration and at 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00, 34:00, 47:00, 71:00, 95:00 and 119:00 h:m after drug administration during Visit 2 and Visit 3. Additionally at 143:00, 167:00, 191:00 and 215:00 h:m after drug administration during Visit 3.

    Time frame: Up to 215 hours (Please check measure description for detailed timeframe)

07

Results

Posted Nov 28, 2025

Participant flow

This was as an open-label, fixed-sequence trial with 2 treatments, administered to healthy male participants to compare itraconazole + BI 1015550 (T) with BI 1015550 alone (R). The BI 1015550 single doses of treatments R and T were separated by a wash-out period of at least 10 days.

Treatment Period 1 + Washout (7 days)
Participant flow — Treatment Period 1 + Washout (7 days)
MilestoneBI 1015550 alone (R) / itraconazole + BI 1015550 (T)
Started16
Completed16
Not completed0
Treatment Period 2 (21 days)
Participant flow — Treatment Period 2 (21 days)
MilestoneBI 1015550 alone (R) / itraconazole + BI 1015550 (T)
Started16
Completed16
Not completed0

Outcome measures

PrimaryArea Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 to 119 Hours

Area under the concentration-time curve of BI 1015550 in plasma over the time interval from 0 to 119 hours (h) (AUC0-119). Standard error is actually geometric standard error. Geometric mean (gMean) is actually adjusted geometric mean. Pharmacokinetic samples were collected at 3:00 hours:minutes (h:m) prior to drug administration and at 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00, 34:00, 47:00, 71:00, 95:00 and 119:00 h:m after drug administration during Visit 2 and Visit 3. Additionally at 143:00, 167:00, 191:00 and 215:00 h:m after drug administration during Visit 3.

Time frame:
Up to 215 hours (Please check measure description for detailed timeframe)
Reported as:
Geometric mean · nanomole (nmol)*h/Litre (L)
Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 to 119 Hours
nanomole (nmol)*h/Litre (L)itraconazole + BI 1015550 (T)BI 1015550 alone (R)
Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 to 119 Hours2073.40 ± NA933.44 ± NA
Statistical analysis
  • itraconazole + BI 1015550 (T) vs BI 1015550 alone (R) · Geometric mean (t/r) ratio (%): 222.13 · 90% CI 203.47 to 242.49To get, gMean ratio (T/R) and confidence interval, least square estimates of log-transformed PK endpoint for T and R were back transformed to original scale. Intra-individual geometric coefficient of variance (%) = 14.2.
PrimaryMaximum Measured Concentration of the BI 1015550 in Plasma

Maximum measured concentration of the BI 1015550 in plasma (Cmax). Standard error is actually geometric standard error. Geometric mean is actually adjusted geometric mean. Pharmacokinetic samples were collected at 3:00 h:m prior to drug administration and at 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00, 34:00, 47:00, 71:00, 95:00 and 119:00 h:m after drug administration during Visit 2 and Visit 3. Additionally at 143:00, 167:00, 191:00 and 215:00 h:m after drug administration during Visit 3.

Time frame:
Up to 215 hours (Please check measure description for detailed timeframe)
Reported as:
Geometric mean · nmol/L
Maximum Measured Concentration of the BI 1015550 in Plasma
nmol/Litraconazole + BI 1015550 (T)BI 1015550 alone (R)
Maximum Measured Concentration of the BI 1015550 in Plasma162.39 ± NA126.91 ± NA
Statistical analysis
  • itraconazole + BI 1015550 (T) vs BI 1015550 alone (R) · Geometric mean (t/r) ratio (%): 127.96 · 90% CI 117.65 to 139.17To get, gMean ratio (T/R) and confidence interval, least square estimates of log-transformed PK endpoint for T and R were back transformed to original scale. Intra-individual geometric coefficient of variance (%) = 13.6.
SecondaryArea Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)

Area under the concentration-time curve of BI 1015550 in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf). Standard error is actually geometric standard error. Geometric mean is actually adjusted geometric mean. Pharmacokinetic samples were collected at 3:00 h:m prior to drug administration and at 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00, 34:00, 47:00, 71:00, 95:00 and 119:00 h:m after drug administration during Visit 2 and Visit 3. Additionally at 143:00, 167:00, 191:00 and 215:00 h:m after drug administration during Visit 3.

Time frame:
Up to 215 hours (Please check measure description for detailed timeframe)
Reported as:
Geometric mean · nmol*h/L
Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)
nmol*h/Litraconazole + BI 1015550 (T)BI 1015550 alone (R)
Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)2183.22 ± NA952.27 ± NA
Statistical analysis
  • itraconazole + BI 1015550 (T) vs BI 1015550 alone (R) · Geometric mean (t/r) ratio (%): 229.26 · 90% CI 207.82 to 252.93To get, gMean ratio (T/R) and confidence interval, least square estimates of log-transformed PK endpoint for T and R were back transformed to original scale. Intra-individual geometric coefficient of variance (%) = 15.9.

Adverse events

Collected over From the first BI 1015550 administration until end of trial, up to 28 days (i.e. 7 days for BI 1015550, 3 days for itraconazole and up to 18 days for itraconazole + BI 1015550).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BI 10155500/16 (0%)0/16 (0%)5/16 (31.3%)
itraconazole0/16 (0%)0/16 (0%)5/16 (31.3%)
itraconazole + BI 10155500/16 (0%)0/16 (0%)9/16 (56.3%)
Most frequent other events
Most frequent other events
EventBI 1015550itraconazoleitraconazole + BI 1015550
DiarrhoeaGastrointestinal disorders2/161/165/16
NauseaGastrointestinal disorders0/162/160/16
NasopharyngitisInfections and infestations0/160/162/16
HeadacheNervous system disorders2/160/162/16
ConjunctivitisInfections and infestations1/160/160/16
Pulpitis dentalInfections and infestations0/161/160/16
RhinitisInfections and infestations0/161/160/16
ThirstGeneral disorders1/160/160/16
Sleep disorderPsychiatric disorders1/160/160/16

Baseline characteristics

Treated set (TS): This subject set included all subjects who were dispensed trial medication and were documented to have taken at least 1 dose of investigational treatment.

Age, Continuous
Age, Continuous(Years)BI 1015550 Alone (R) / Itraconazole + BI 1015550 (T)
Mean42.3 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)BI 1015550 Alone (R) / Itraconazole + BI 1015550 (T)
Female0
Male16
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BI 1015550 Alone (R) / Itraconazole + BI 1015550 (T)
Hispanic or Latino0
Not Hispanic or Latino16
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BI 1015550 Alone (R) / Itraconazole + BI 1015550 (T)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White16
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Humanpharmakologisches Zentrum Biberach
    Biberach, 88397, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Jul 2018, 2 months.

Results were first posted in Nov 2025, 7 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2018
First posted
Jan 18, 2018
StartActual
May 3, 2018
Primary completionActual
Jul 20, 2018
CompletionActual
Jul 20, 2018
Results first posted
Nov 28, 2025
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03403439
Responsible party
Sponsor
First posted
Jan 18, 2018
Start date
May 3, 2018
Primary completion
Jul 20, 2018
Completion
Jul 20, 2018
Results posted
Nov 28, 2025
Last update
Nov 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion